Antibacterial oxazolidinones: emerging structure–toxicity relationships

References

• Barbachyn MR, Ford CW. Oxazolidinone structure–ractivity relationships leading to linezolid. Angew. Chem. Int. Ed. Engl.42(18), 2010–2023 (2003).
   PubMed Web of Science ®Google Scholar
• Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious Gram-positive infections. J. Med. Chem.51(7), 1981–1990 (2008).
   PubMed Web of Science ®Google Scholar
• Leach KL, Swaney SM, Colca JR et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell.26(3), 393–402 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc. Natl Acad. Sci. USA105(36), 13339–13344 (2008).
   PubMed Web of Science ®Google Scholar
• Ippolito JA, Kanyo ZF, Wang D et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem.51(12), 3353–3356 (2008).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother.51(Suppl. 2), ii9–ii16 (2003).
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother.51(Suppl. 2), ii17–ii25 (2003).
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J. Antimicrob. Chemother.51(Suppl. 2), ii27–ii35 (2003).
   PubMedGoogle Scholar
• French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother.51(Suppl. 2), ii45–ii53 (2003).
   PubMed Web of Science ®Google Scholar
• Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy27(8), 1189–1197 (2007).
   PubMed Web of Science ®Google Scholar
• Naruganahalli KS, Shirumalla RK, Bansal V, Gupta JB, Das B, Ray A. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats. Eur. J. Pharmacol.545(2–3), 167–172 (2006).
   PubMedGoogle Scholar
• Hutchinson DK. Oxazolidinone antibacterial agents: a critical review. Curr. Top. Med. Chem.3(9), 1021–1042 (2003).
   PubMed Web of Science ®Google Scholar
• Gravestock MB. Recent developments in the discovery of novel oxazolidinone antibacterials. Curr. Opin. Drug Discov. Devel.8(4), 469–477 (2005).
   PubMedGoogle Scholar
• Renslo AR, Luehr GW, Gordeev MF. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg. Med. Chem.14(12), 4227–4240 (2006).
   PubMed Web of Science ®Google Scholar
• Vara Prasad JVN. New oxazolidinones. Curr. Opin. Microbiol.10, 454–460 (2007).
   PubMed Web of Science ®Google Scholar
• Srivastava BK, Soni R, Patel JZ, Jain MR, Patel PR. Oxazolidinone Antibacterials and Our Experience. Anti Infect. Agents Med. Chem.7, 258–280 (2008).
   Google Scholar
• Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother.58(2), 273–280 (2006).
   PubMed Web of Science ®Google Scholar
• Nam JR, Kim MS, Lee CH, Whang DH. Linezolid treatment for osteomyelitis due to staphylococcus epidermidis with reduced vancomycin susceptibility. J. Korean Neurosurg. Soc.43(6), 307–310 (2008).
   PubMedGoogle Scholar
• Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf.31(9), 753–768 (2008).
   PubMed Web of Science ®Google Scholar
• Skripkin E, McConnell TS, DeVito J et al. R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. Antimicrob. Agents Chemother.52(10), 3550–3557 (2008).
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Poppe S, Schaadt R et al.In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother.52(12), 4442–4447 (2008).
   PubMed Web of Science ®Google Scholar
• Surber J, Mehra P, Manos P et al. Efficacy of TR-701 in an Phase 2 randomized, double-blind study in patients with severe complicated skin and skin structure infections (cSSSI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• File T, Bagheri F, Bush L et al. A Phase 2 Study comparing two doses of radezolid to linezolid in adults with uncomplicated skin and skin structure infections (uSSSI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Prokocimer P, Bien P, Munoz KA, Aster R. Hematological Effects of TR-701, linezolid, and placebo administered for 21 days in healthy subjects. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 12–14 September 2008.
   Google Scholar
• Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob. Agents Chemother.52(5), 1653–1662 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou J, Bhattacharjee A, Chen S et al. Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics. Bioorg. Med. Chem. Lett.18(23), 6175–6178 (2008).
   PubMed Web of Science ®Google Scholar
• Sciotti RJ, Pliushchev M, Wiedeman PE et al. The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class. Bioorg. Med. Chem. Lett.12(16), 2121–2123 (2002).
   PubMed Web of Science ®Google Scholar
• McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother.50(6), 2042–2049 (2006).
   PubMed Web of Science ®Google Scholar
• Nagiec EE, Wu L, Swaney SM et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob. Agents Chemother.49(9), 3896–3902 (2005).
   PubMed Web of Science ®Google Scholar
• Renslo AR, Atuegbu A, Herradura P et al. A distal methyl substituent attenuates mitochondrial protein synthesis inhibition in oxazolidinone antibacterials. Bioorg. Med. Chem. Lett.17(18), 5036–5040 (2007).
   PubMedGoogle Scholar
• Cho YL, Chae SE, Baek SY et al. New oxazolidinones with cyclic amidrazone (i): structure-activity relationship of cyclic amidrazone antibiotics. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Lee H, Cha DS, Kang D-H et al. New oxazolidinones with cyclic amidrazone (III): pharmacokinetics and repeated dose toxicity studies of LCB01-0183 and LCB01-0371. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Reck F, Zhou F, Girardot M et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J. Med. Chem.48(2), 499–506 (2005).
   PubMed Web of Science ®Google Scholar
• Poel TJ, Thomas RC, Adams WJ et al. Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound. J. Med. Chem.50(24), 5886–5889 (2007).
   PubMedGoogle Scholar
• Penzien JB, Huband M, Leach K et al.In vitro and in vivo activity of PF-00708093 and PF-02341752: new oxazolidinone antibacterials versus recent bacterial clinical isolates. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Choy A, Colbry N, Huber C, Pamment M, Duine JV. Development of a synthesis for a long-term oxazolidinone antibacterial. Org. Process Res. Dev.12(5), 884–887 (2008).
   Google Scholar